

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations
All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400
Please be sure to complete the following:

Company name **caVos Biotechnology** * Website **N/A** *

CEO name **Haim Belinson**

Select a CATEGORY: **Biotech/Pharma** *
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- **Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities**

You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:

- Executive Summary / Investment Rational

CaVos Biotech is at the forefront of genomic and data science focusing on the development of a multi-level genomic algorithm to uncover the genetic base of extraordinary cancer resistance found in various animal species. Our focus extends to developing innovative therapeutics inspired by natural resistance mechanisms against various diseases.

- Core Technology

Harnessing the wealth of genetic data spanning hundreds of species, our proprietary multi-level genomic algorithm integrates advanced computational techniques and comparative genomics. This approach identifies evolutionary conserved pivotal anti-cancer genetic variations. Our framework reveals novel anti-cancer mechanisms and opens the possibility to develop new extremely efficient drugs with potentially very low side effects.

- Product Profile/Pipeline

We leveraged our powerful computational engine to identify a proprietary list of single-amino-acid changes in 100 proteins that are tightly associated with a stronger anti-cancer phenotype. We experimentally demonstrated that these single amino acid substitutions conserve normal protein function in human cells while dramatically reducing numerous cancerous traits.

- **Business Strategy** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.
- **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**

Building on these insights, CaVos is at preclinical stage, developing RNA-based therapeutics designed to target human cancer by introducing these anti-cancer proteins. Our cutting-edge approach offers the potential to transform cancer treatment and provide innovative solutions in precision medicine, diagnostics, and prognostics.